Abstract
Background
Patients with aneurysmal subarachnoid hemorrhage (aSAH) with electroencephalographic epileptiform activity (seizures, periodic and rhythmic patterns, and sporadic discharges) are frequently treated with antiseizure medications (ASMs). However, the safety and effectiveness of ASM treatment for epileptiform activity has not been established. We used observational data to investigate the effectiveness of ASM treatment in patients with aSAH undergoing continuous electroencephalography (cEEG) to develop a causal hypothesis for testing in prospective trials.
Methods
This was a retrospective single-center cohort study of patients with aSAH admitted between 2011 and 2016. Patients underwent ≥ 24 h of cEEG within 4 days of admission. All patients received primary ASM prophylaxis until aneurysm treatment (typically within 24 h of admission). Treatment exposure was defined as reinitiation of ASMs after aneurysm treatment and cEEG initiation. We excluded patients with non-cEEG indications for ASMs (e.g., epilepsy, acute symptomatic seizures). Outcomes measures were 90-day mortality and good functional outcome (modified Rankin Scale scores 0–3). Propensity scores were used to adjust for baseline covariates and disease severity.
Results
Ninety-four patients were eligible (40 continued ASM treatment; 54 received prophylaxis only). ASM continuation was not significantly associated with higher 90-day mortality (propensity-adjusted hazard ratio [HR] = 2.01 [95% confidence interval (CI) 0.57–7.02]). ASM continuation was associated with lower likelihood for 90-day good functional outcome (propensity-adjusted HR = 0.39 [95% CI 0.18–0.81]). In a secondary analysis, low-intensity treatment (low-dose single ASM) was not significantly associated with mortality (propensity-adjusted HR = 0.60 [95% CI 0.10–3.59]), although it was associated with a lower likelihood of good outcome (propensity-adjusted HR = 0.37 [95% CI 0.15–0.91]), compared with prophylaxis. High-intensity treatment (high-dose single ASM, multiple ASMs, or anesthetics) was associated with higher mortality (propensity-adjusted HR = 6.80 [95% CI 1.67–27.65]) and lower likelihood for good outcomes (propensity-adjusted HR = 0.30 [95% CI 0.10–0.94]) compared with prophylaxis only.
Conclusions
Our findings suggest the testable hypothesis that continuing ASMs in patients with aSAH with cEEG abnormalities does not improve functional outcomes. This hypothesis should be tested in prospective randomized studies.
Similar content being viewed by others
References
Claassen J, Hirsch LJ, Frontera JA, Fernandez A, Schmidt M, Kapinos G, Wittman J, et al. Prognostic significance of continuous EEG monitoring in patients with poor-grade subarachnoid hemorrhage. Neurocrit Care. 2006;4:103–12.
Zafar SF, Postma EN, Biswal S, Boyle EJ, Bechek S, O’Connor K, Shenoy A, et al. Effect of epileptiform abnormality burden on neurologic outcome and antiepileptic drug management after subarachnoid hemorrhage. Clin Neurophysiol. 2018;129:2219–27.
De Marchis GM, Pugin D, Meyers E, Velasquez A, Suwatcharangkoon S, Park S, Falo MC, et al. Seizure burden in subarachnoid hemorrhage associated with functional and cognitive outcome. Neurology. 2016;86:253–60.
Naidech AM, Kreiter KT, Janjua N, Ostapkovich N, Parra A, Commichau C, Connolly ES, et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke. 2005;36:583–7.
Yoon SJ, Joo JY, Kim YB, Hong CK, Chung J. Effects of prophylactic antiepileptic drugs on clinical outcomes in patients with a good clinical grade suffering from aneurysmal subarachnoid hemorrhage. J Cerebrovasc Endovasc Neurosurg. 2015;17(3):166–72.
Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, Hoh BL, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43:1711–37.
Kim JA, Rosenthal ES, Biswal S, Zafar S, Shenoy AV, O’Connor KL, Bechek SC, et al. Epileptiform abnormalities predict delayed cerebral ischemia in subarachnoid hemorrhage. Clin Neurophysiol. 2017;128:1091–9.
Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijdicks EF, Muizelaar JP, Mendelow AD, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41:2391–5.
Rosenthal ES, Biswal S, Zafar SF, O’Connor KL, Bechek S, Shenoy AV, et al. Continuous electroencephalography predicts delayed cerebral ischemia after subarachnoid hemorrhage: a prospective study of diagnostic accuracy. Ann Neurol. 2018;83:958–69.
Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29.
Hunt WE, Hess RM. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg. 1968;28:14–20.
Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery. 1980;6:1–9.
Witsch J, Frey HP, Patel S, Park S, Lahiri S, Schmidt JM, Agarwal S, et al. Prognostication of long-term outcomes after subarachnoid hemorrhage: the FRESH score. Ann Neurol. 2016;80:46–58.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
Zafar S, Westover MB, Gaspard N, Gilmore E, Foreman B, O’Connor K, Rosenthal ES. Inter-rater agreement for consensus definitions of delayed ischemic events following aneurysmal subarachnoid hemorrhage. J Clin Neurophysiol. 2016;33:235.
Hirsch LJ, LaRoche SM, Gaspard N, Gerard E, Svoronos A, Herman ST, Mani R, et al. American clinical neurophysiology society’s standardized critical care EEG terminology: 2012 version. J Clin Neurophysiol. 2013;30:1–27.
Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044–54.
Patel N, Rao VA, Heilman-Espinoza ER, Lai R, Quesada RA, Flint AC. Simple and reliable determination of the modified rankin scale score in neurosurgical and neurological patients: the mRS-9Q. Neurosurgery. 2012;71:971–5.
Zafar SF, Postma EN, Biswal S, Fleuren L, Boyle EJ, Bechek S, O’Connor K, et al. Electronic health data predict outcomes after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2018;28:184–93.
Adams HP, Kassell NF, Torner JC, Haley EC. Predicting cerebral ischemia after aneurysmal subarachnoid hemorrhage: influences of clinical condition, CT results, and antifibrinolytic therapy. A report of the Cooperative Aneurysm Study. Neurology. 1987;37:1586–91.
Kilbride RD, Costello DJ, Chiappa KH. How seizure detection by continuous electroencephalographic monitoring affects the prescribing of antiepileptic medications. Arch Neurol. 2009;66:723–8.
Alvarez V, Ruiz AA, LaRoche S, Hirsch LJ, Parres C, Voinescu PE, Fernandez A, et al. The use and yield of continuous EEG in critically ill patients: a comparative study of three centers. Clin Neurophys. 2017;128:570–8.
Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D. Quality of life of people with epilepsy: a European study. Epilepsia. 1997;38:353.
Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet. 1995;345:476–9.
Perucca P, Carter J, Vahle V, Gilliam FG. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology. 2009;72:1223–9.
Rubinos C, Reynolds AS, Claassen J. The ictal–interictal continuum: to treat or not to treat (and how)? Neurocrit care. 2018;29:3–8.
Struck AF, Westover MB, Hall LT, Deck GM, Cole AJ, Rosenthal ES. Metabolic correlates of the ictal-interictal continuum: FDG-PET during continuous EEG. Neurocrit care. 2016;24:324–31.
Vespa P, Tubi M, Claassen J, Buitrago-Blanco M, McArthur D, Velazquez AG, Tu B, et al. Metabolic crisis occurs with seizures and periodic discharges after brain trauma. Ann Neurol. 2016;79:579–90.
Witsch J, Frey H, Schmidt JM, Velazquez A, Falo CM, Reznik M, Roh D, et al. Electroencephalographic periodic discharges and frequency-dependent brain tissue hypoxia in acute brain injury. JAMA Neurol. 2017;74:301–9.
Macdonald RL. Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol. 2014;10:44.
Funding
This study received research support from National Institutes of Health Grant K23NS114201 (to Dr. Zafar).
Author information
Authors and Affiliations
Contributions
Dr. Zafar contributed to the conception and design of the study, data collection and analysis, interpretation of data, drafting of the manuscript, and preparation of figures. Dr. Rosenthal contributed to data collection, interpretation of data, and revision of the manuscript for intellectual content. Dr. Postma contributed to data collection, interpretation of data, and revision of the manuscript for intellectual content. Dr. Sanches contributed to data collection, interpretation of data, and revision of the manuscript for intellectual content. Dr. Ayub contributed to data collection, interpretation of data, and revision of the manuscript for intellectual content. Dr. R contributed to data collection, interpretation of data, and revision of the manuscript for intellectual content. Dr. Kim contributed to data collection and interpretation and revision of the manuscript for intellectual content. Dr. Rubin contributed to data collection and interpretation and revision of the manuscript for intellectual content. Dr. Lee contributed statistical analysis, interpretation of data, and revision of the manuscript for intellectual content. Dr. Patel contributed to data collection and revision of the manuscript for intellectual content. Dr. Hsu contributed to study design, interpretation, and revision of the manuscript for intellectual content. Dr. Patorno contributed to study design, analysis, interpretation, and revision of the manuscript for intellectual content. Dr. Westover contributed to study design, analysis, interpretation of data, and revision of the manuscript for intellectual content. The final manuscript was approved by all authors.
Corresponding author
Ethics declarations
Conflict of interest
Dr. Zafar is supported by National Institutes of Health grant K23NS114201. Dr. Zafar is a clinical neurophysiologist for Corticare, unrelated to this work. Dr. Rosenthal received consulting fees from UCB Pharma, Inc., and Ceribell, Inc., unrelated to this work. Dr. Postma reports no disclosures. Dr. Sanches reports no disclosures. Dr. Ayub reports no disclosures. Dr. R reports no disclosures. Dr. Kim reports no disclosure. Dr. Rubin has a pending patent for “System and Method for Determining Treatment Outcomes for Neurological Disorders Based on Functional Connectivity Parameters.” Dr. Lee reports no disclosures. Dr. Patel reports no disclosures. Dr. Hsu reports grants from the National Institutes of Health (P01AG032952 and R01AG062282). Dr. Patorno is supported by K08AG055670 from the National Institute on Aging and is the investigator of an investigator-initiated grant to the Brigham and Women’s Hospital from Boehringer Ingelheim, not related to this work. Dr. Westover is cofounder of Beacon Biosignals, unrelated to this work, and was supported by the Glenn Foundation for Medical Research and the American Federation for Aging Research (Breakthroughs in Gerontology Grant); the American Academy of Sleep Medicine (AASM Foundation Strategic Research Award); the Football Players Health Study (FPHS) at Harvard University; the Department of Defense through a subcontract from Moberg ICU Solutions, Inc.; and the National Institutes of Health (1R01NS102190, 1R01NS102574, 1R01NS107291, 1RF1AG064312).
Ethical approval/informed consent
This article adheres to ethical guidelines. The study was approved by the Institutional Review Board of Mass General Brigham. Informed consent was not required for this retrospective study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Zafar, S.F., Rosenthal, E.S., Postma, E.N. et al. Antiseizure Medication Treatment and Outcomes in Patients with Subarachnoid Hemorrhage Undergoing Continuous EEG Monitoring. Neurocrit Care 36, 857–867 (2022). https://doi.org/10.1007/s12028-021-01387-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12028-021-01387-x